Why Indian drugmakers are losing pricing power in the US
New Delhi, Nov. 17 -- Indian drugmakers are losing pricing power in the US, their largest market, as buyer concentration and intensifying competition squeeze sales and margins. In the July-September 2026 quarter, Cipla's North America revenue fell 19% in rupee terms as sales of generic Revlimid, a blood cancer drug, declined amid competition. Revlimid also weighed on Dr. Reddy's North America sales, while Lupin's US sales fell 13% from the April-June quarter after it lost exclusivity on Tolvaptan and Mirabegron.
The pressure is structural. A handful of buying groups dominate drug purchases in the US, while competition is eroding prices faster than companies can replace lost revenue. Indian drugmakers are increasingly shifting towards com...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.